Webpackaging logo

Aptar Pharma showcases expanded portfolio of respiratory innovations and services

  • Aptar Pharma
Europe, UK, Ireland, Scotland, Health, Pharmaceuticals, Shows, Associations, Media, Packaging Trade Shows, Events

Aptar Pharma, a leading drug delivery systems provider, announces its Platinum Sponsorship of this year’s Drug Delivery to the Lung (DDL) Conference 2019, which takes place from December 11-13 in Edinburgh, Scotland.

DDL provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in the development of inhalation medicines. Aptar Pharma will exhibit its broad respiratory portfolio and showcase its latest drug delivery innovations and services for respiratory devices at the three-day conference, which is celebrating its 30th anniversary this year.

A worldwide leader in respiratory drug delivery devices for the treatment of asthma and COPD, Aptar Pharma will exhibit at Booth 432 at DDL, where their team of experts will showcase their innovative range of respiratory drug delivery systems and connected devices that help improve adherence and patient health outcomes.

Noble International, a global leader in drug delivery device trainers and patient onboarding and the latest addition to the Aptar Pharma family, will also be on exhibit at Booth 432, where their trainer platforms for respiratory devices to help improve patient adherence and health outcomes will be on display.

Also exhibiting alongside Aptar Pharma at Booth 432 will be Aptar CSP Technologies, the active packaging specialists, who will be on hand to explain how their patented 3-Phase Activ-Polymer™ platform technology can provide innovative solutions for protecting respiratory products from moisture, oxygen and VOCs in order to extend shelf life and improve their performance.

Aptar Pharma’s newly expanded Aptar Pharma Services platform will also be highlighted at DDL 2019. Leading experts from Aptar Pharma companies Nanopharm, Next Breath and Gateway Analytical will be on hand to discuss how their value-added services can help customers accelerate and derisk their drug development journey:

  • Nanopharm, a leading provider of orally inhaled and nasal drug product design and development services, will exhibit at Booth 518
  • Next Breath, a full-service cGMP lab specializing in analytical testing of drug delivery systems, will exhibit at Booth 516
  • Gateway Analytical, providing industry-leading particulate detection and predictive analytical services, will exhibit at Booth 514.

To further share its expertise in respiratory drug delivery with the scientific community, Aptar Pharma will be presenting five scientific posters during DDL 2019. Delegates and attendees will have the opportunity to view them during the dedicated poster sessions, which will take place daily at the Conference:

  • “Method Suitability for Actuation Force Study for Unidose Nasal Sprays” (Poster No.12), presented by NextBreath, an Aptar Pharma company
  • “Investigating the Effect of Nasal Suspension Rheology on API Particle Size and Dissolution Properties” (Poster No. 29), presented by Nanopharm, an Aptar Pharma company
  • “Investigating the Regional Deposition and Simulated Inhaled Pharmacokinetic Profiles of Generic Dry Powder Inhalers” (Poster No. 57), presented by Aptar Pharma and Nanopharm, an Aptar Pharma company
  • “Describing the Dissolution of a Poorly Soluble Inhaled Corticosteroid Using a Mixed Kinetic Control Model” (Poster No. 66), presented by Nanopharm, an Aptar Pharma company
  • “Leachables Measurements from Hydrofluoroalkane 152a Metered Dose Inhalers” (Poster No. 79), presented by Aptar Pharma

Guillaume Brouet, Vice-President Regulatory, Analytical & Scientific Affairs at Aptar Pharma, commented, “As a leader in inhalation drug delivery systems, we are proud to be a Platinum Sponsor of DDL this year. We look forward to showcasing our expanded Aptar Pharma device, technologies and services offering, which provide complete solutions for customers and further support their respiratory drug development journeys”.

Aptar Pharma is also a sponsor of the special DDL 2019 Dinner celebrating DDL’s 30th Anniversary, which will take place on Thursday, December 12th and to which all delegates and exhibitors are invited.

See also

Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives for prescription and OTC products.

Aptar’s Nasal Unidose Device approved by US FDA

AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

Join Aptar Pharma's live webinar "Good medicine: Solutions for sensitive injectable formulations"

Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk. Taking place on October 24, 2018, at 15.00 GMT, the webinar, entitled “Good Medicine: Solutions for Sensitive Injectable Formulations” will demonstrate how high quality film coated components meet compliance expectations while maintaining safety of supply for the drug product..

Aptar Pharma's electronic lockout device approved by EMA

Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.

  • Company News
  • English
  • Modified 26 Nov 2019
  • Hits 268